Welcome to our dedicated page for Enliven Therapeutics SEC filings (Ticker: ELVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enliven Therapeutics, Inc. (Nasdaq: ELVN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Enliven files a range of documents with the U.S. Securities and Exchange Commission (SEC), including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K describing material events.
For Enliven, Form 8-K filings are particularly relevant to investors monitoring clinical-stage and corporate milestones. Recent 8-Ks have covered topics such as quarterly financial results, leadership changes including the appointment of a new President and Chief Executive Officer, the adoption of the 2025 Inducement Equity Incentive Plan, and related compensatory arrangements. Amendments on Form 8-K/A may be used to correct or update previously furnished information, such as earnings press releases.
Periodic reports on Form 10-K and Form 10-Q (referenced in Enliven’s press releases) contain more detailed information on research and development expenses, general and administrative costs, net loss, cash, cash equivalents and marketable securities, as well as risk factors and management’s discussion and analysis. These filings help contextualize the company’s ability to fund the ENABLE Phase 1 trial of ELVN-001 and potential future studies.
On Stock Titan, users can review Enliven’s SEC filings alongside AI-powered summaries that explain key points in accessible language, highlight important sections, and help interpret complex disclosures. Real-time updates from EDGAR allow quick access to new filings, while specialized forms such as Form 4 (when available) can be used to track insider equity transactions. This page is a practical starting point for understanding Enliven’s regulatory history, financial reporting, equity plans and material corporate events related to its precision oncology programs.
Enliven Therapeutics submitted a Form 144 disclosing a proposed sale of 25,000 shares of Common Stock through Jefferies LLC, with an aggregate value listed as $914,750 and an entry date of 03/31/2026 on Nasdaq.
The filing also lists recent sales by Joseph Lyssikatos: 41,302 shares on 01/08/2026 for $993,437.48 and 91,198 shares on 01/09/2026 for $2,482,579.19, plus several other dispositions in January–February 2026.
Andrew Phillips files a Form 144 proposing sale of 26,035 shares of Common Stock. The filing shows 26,035 shares to be sold via a Stock Option Exercise on 03/31/2026 with cash proceeds to the issuer. The notice also lists prior sales of 21,844 and 1,520 shares on 02/02/2026 and 01/22/2026, respectively.
Enliven Therapeutics’ chief medical officer Helen Louise Collins exercised stock options and sold shares in a planned transaction. She exercised options for 40,000 shares of common stock at an exercise price of $2.48 per share and sold 40,000 shares at a weighted average price of $35.1006 per share. The filing states these trades were made under a Rule 10b5-1 trading plan adopted on October 19, 2025, indicating they were pre-scheduled. Following the transactions, Collins directly owns 25,000 shares of common stock and continues to hold 136,268 equity awards, including fully vested options and RSUs.
Enliven Therapeutics, Inc. filed a Section 144 notice reporting proposed and recent sales of Common Stock by an affiliate through Jefferies LLC.
The filing lists a proposed sale of 45,000 shares with a related value of $1,401,750.00 and trade/broker details noting Nasdaq and a filing date of 03/25/2026. The filing also discloses prior sales by Helen Collins of 45,000, 29,871, 10,129, and 5,000 shares on 02/17/2026, 03/09/2026, 03/10/2026, and 03/17/2026 respectively, with the dollar amounts shown for each transaction.
Enliven Therapeutics filed a Form 144 to sell 100,000 common shares. The notice lists these as founder shares with Jefferies LLC as broker and an intended sale on 03/24/2026 on Nasdaq.
The filing also discloses a prior sale of 48,300 shares by Anish Patel on 01/09/2026 for $1,351,761.47. The filing presents the proposed sale quantity and a recent disposition by an insider.
Enliven Therapeutics Chief Medical Officer Helen Louise Collins exercised stock options for 5,000 shares of Common Stock at an exercise price of $2.4800 per share, then sold 5,000 shares at a weighted average price of $27.7600 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on October 19, 2025. Following the sale, Collins directly holds 25,000 shares of Common Stock, and the filing shows no remaining derivative securities from this option after the exercise.
Enliven Therapeutics’ chief medical officer Helen Louise Collins exercised stock options for 40,000 shares of Common Stock at an exercise price of $2.48 per share, then sold 40,000 shares in open‑market trades at weighted average prices around $30.
The transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on October 19, 2025. After these trades, Collins holds 25,000 shares of Enliven Therapeutics Common Stock directly.
Enliven Therapeutics’ chief financial officer, Benjamin Hohl, sold 10,000 shares of common stock in an open-market transaction on March 6, 2026, at a weighted-average price of $29.5839 per share. After this sale, he directly owned 51,000 shares. The transaction was executed in multiple trades within a price range of $29.43 to $29.7867.
Enliven Therapeutics, Inc. filing under Form 144 reports proposed resale transactions involving common stock. The filing lists 45,000 shares to be sold through Jefferies LLC with an aggregate amount of $1,324,800.00 and a figure 59,000,000 on 03/09/2026. The filing also itemizes recent sales by Helen Collins: 5,000 shares for $130,878.30 and 40,000 shares for $1,046,985.20 on 02/17/2026.